Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 3, 2009, Pages 854-861

  Wachsberger, Phyllis ^a   Burd, Randy ^b   Ryan, Anderson ^c   Daskalakis, Constantine ^a   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis inhibitor; CPT 11; LoVo colorectal cancer; Radiotherapy; Vandetanib

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTITUMOR EFFECT; ATHYMIC; COLORECTAL CANCER; COLORECTAL TUMORS; CPT-11; CYTOTOXIC; HIND LIMBS; INTRAPERITONEALLY; IRINOTECAN; LOVO CELLS; LOVO COLORECTAL CANCER; PHOSPHATE-BUFFERED SALINES; RECEPTOR TYROSINE KINASE; TUMOR GROWTH; TUMOR VOLUMES; VANDETANIB;

AMINO ACIDS; CHARGE TRAPPING; GROWTH KINETICS; ONCOLOGY; RADIATION EFFECTS; RADIOTHERAPY;

TUMORS;

IRINOTECAN; VANDETANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; MICE; MICE, NUDE; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349546300     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.016     Document Type: Article

References (42)

1. Tewes M., Schleucher N., Achterrath W., et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: Results of an extended phase I study. Ann Oncol 14 (2003) 1442-1448
2. Roberts R.B., Min L., Washington M.K., et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A 99 (2002) 1521-1526
3. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
4. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
5. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 (2002) 7284-7290
6. Ciardiello F., Caputo R., Damiano V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9 (2003) 1546-1556
7. Ryan A.J., and Wedge S.R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 Suppl 1 (2005) S6-S13
8. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 (2002) 4645-4655
9. Brazelle W.D., Shi W., and Siemann D.W. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 836-841
10. Damiano V., Melisi D., Bianco C., et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11 (2005) 5639-5644
11. Frederick B., Gustafson D., Bianco C., et al. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys 64 (2006) 33-37
12. Sandstrom M., Johansson M., Bergstrom P., et al. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 88 (2008) 1-9
13. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
14. Koizumi F., Kanzawa F., Ueda Y., et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 108 (2004) 464-472
15. Nyati M.K., Maheshwari D., Hanasoge S., et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10 (2004) 691-700
16. Gustafson D.L., Bradshaw-Pierce E.L., Merz A.L., et al. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. J Pharmacol Exp Ther 318 (2006) 872-880
17. Morelli M.P., Cascone T., Troiani T., et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208 (2006) 344-353
18. Morabito A., Piccirillo M.C., Falasconi F., et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. Oncologist 14 (2009) 378-390
19. Michael M., Gibbs P., Smith R., et al. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs 27 (2009) 253-261
20. Natale R.B., Bodkin D., Govindan R., et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized Phase II Study. J Clin Oncol 27 (2009) 2523-2529
21. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
22. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
23. Senan S., and Smit E.F. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12 (2007) 465-477
24. Shibuya K., Komaki R., Shintani T., et al. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69 (2007) 1534-1543
25. Pennell N.A., and Lynch Jr. T.J. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14 (2009) 399-411
26. Troiani T., Serkova N.J., Gustafson D.L., et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 13 (2007) 6450-6458
27. Bianco C., Giovannetti E., Ciardiello F., et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 12 (2006) 7099-7107
28. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
29. Paris F., Fuks Z., Kang A., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293 (2001) 293-297
30. Balaban N., Moni J., Shannon M., et al. The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1314 (1996) 147-156
31. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
32. Van S.S., Kyula J., Kelly D.M., et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5 (2006) 1154-1165
33. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Squamous cell head and neck cancer: Evidence of angiogenic regeneration during radiotherapy. Anticancer Res 21 (2001) 4301-4309
34. Taylor A.P., Osorio L., Craig R., et al. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin Cancer Res 8 (2002) 1213-1222
35. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
36. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008) 592-603
37. Casanovas O., Hicklin D.J., Bergers G., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
38. Du R., Lu K.V., Petritsch C., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008) 206-220
39. Sasaki T., Tanno S., Shibukawa K., et al. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. Int J Oncol 33 (2008) 525-532
40. Showalter TN, Daroczi B, Halko R, et al. ZD6474 enhances radiation therapy in human glioblastoma xenografts which contain the EGFRvIII mutation or overexpress wtEGFR. Abstract, Radiation Research Society Annual Meeting 2008 (Boston, MA) Radiation Research Society Annual Meeting 2008.
41. Komarova N.L., Katouli A.A., and Wodarz D. Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS ONE 4 (2009) e4423
42. Okabe T., Okamoto I., Tsukioka S., et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 15 (2009) 907-913